Tatva Chintan Pharma Chem · NSE: TATVA · BSE: 543321
Q3 FY23 results · Oct–Dec 2022
Tatva Chintan Pharma Chem reported revenue from operations of ₹120.61 crore (up 15.2% from Q3 FY22) and net profit of ₹11.62 crore (down 49.0% from Q3 FY22) for Q3 FY23 (Oct–Dec 2022), on a consolidated basis.
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 120.61 | 104.67 | +15.2% | 90.09 | +33.9% |
| Other income | 1.52 | 4.72 | −67.8% | 1.55 | −1.9% |
| Total income | 122.13 | 109.39 | +11.6% | 91.64 | +33.3% |
| Profit before tax | 14.22 | 25.47 | −44.2% | 9.06 | +57.0% |
| Net profit for the period | 11.62 | 22.81 | −49.0% | 7.11 | +63.4% |
| EPS, basic (₹) | 5.24 | 10.29 | −49.1% | 3.21 | +63.2% |
| Net margin (%) | 9.6 | 21.8 | 7.9 |
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 113.54 | 101.59 | +11.8% | 84.04 | +35.1% |
| Other income | 1.07 | 5.08 | −78.9% | 1.55 | −30.7% |
| Total income | 114.61 | 106.67 | +7.4% | 85.59 | +33.9% |
| Profit before tax | 13.15 | 24.77 | −46.9% | 6.81 | +93.0% |
| Net profit for the period | 10.56 | 22.43 | −52.9% | 5.26 | +100.9% |
| EPS, basic (₹) | 4.76 | 10.12 | −53.0% | 2.37 | +100.8% |
| Net margin (%) | 9.3 | 22.1 | 6.3 |
Consolidated
- Filed with BSE
- 25 Jan 2023, 15:47 IST
- Board meeting
- 24 Jan 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 25 Jan 2023, 15:47 IST
- Board meeting
- 24 Jan 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE